Clinical trials
Cisplatin clinical trials
Below are recruiting cisplatin clinical trials, each written for real people, not researchers. We’re tracking 486 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05491512RecruitingPhase 2
Reduced radiation with chemo for HPV throat cancer
This trial tests whether giving less radiation (while using standard chemotherapy) can treat HPV-related throat cancer effectively. It may help reduce radiation exposure while still controlling the cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT05494190Recruiting
Treatment strategy for lymph node spread in hypopharyngeal cancer
This trial studies treatment choices for people with hypopharyngeal squamous cell cancer that has spread to certain neck lymph nodes. The goal is to help control the cancer in the neck and improve outcomes when the lymph node area can be surgically managed.
Harbin, HeilongjiangAges 18–75 - NCT05535166RecruitingPhase 2
Risk- and lab-guided treatment for young children with medulloblastoma
This Phase 2 trial tests how doctors choose treatment for infants and young children with newly diagnosed medulloblastoma, based on MRI/CSF staging and lab testing of the tumor. It may help by matching therapy intensity to the child’s specific risk level and tumor type.
Palo Alto, CaliforniaAges Up to 4.9 years - NCT05541016RecruitingPhase 2
Personalized lower-dose radiation for HPV-related throat cancer
This Phase 2 study tests whether giving a less intense (de-escalated) radiation plan can work for certain people with HPV-related oropharyngeal throat cancer. It uses HPV blood testing and scans to help guide treatment, aiming to keep cancer control while reducing treatment side effects.
Scottsdale, ArizonaAges 18 years+ - NCT05570422RecruitingPhase 1
Safety and early benefits of an injection plus radiation for cervical cancer
This Phase 1 study tests whether KRC-01, given by injection into the tumor, is safe and tolerable when combined with standard chemoradiation for locally advanced cervical cancer. It also looks for early signs that the treatment can shrink tumors.
ChandigarhAges 18 years+ - NCT05615818RecruitingPhase 3
Study of targeted drug choices for advanced bile duct cancers
This Phase 3 trial matches people with advanced bile duct cancer or gallbladder cancer to a specific targeted medicine based on their tumor’s lab results. It aims to improve disease control by using the right drug for the specific changes found in the cancer.
BrusselsAges 18 years+ - NCT05624996RecruitingPhase 3
Targeted high-dose radiation added to standard lung cancer treatment
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
Birmingham, AlabamaAges 18 years+ - NCT05655949RecruitingPhase 2
Y-90 radiation plus immunotherapy and chemo for bile duct cancer
This trial studies whether combining Y-90 liver radiation with an immunotherapy drug (durvalumab) and chemo (gemcitabine and cisplatin) can better control locally advanced or metastatic intrahepatic cholangiocarcinoma (bile duct cancer in the liver). It may help shrink tumors and slow disease growth, depending on how well the treatment works for your cancer type and overall health.
Boston, MassachusettsAges 18 years+ - NCT05659381RecruitingPhase 3
Heated belly chemo plus niraparib after interval surgery for ovarian cancer
This Phase 3 study tests whether heated chemotherapy placed inside the belly, followed by interval surgery and the maintenance medicine niraparib, can improve outcomes for certain advanced ovarian, fallopian tube, or primary peritoneal cancers. It focuses on people whose tumors are HRD/LOH positive and who can have all visible disease removed.
Duarte, CaliforniaAges 18 years+ - NCT05674305RecruitingPhase 3
Tested radiation alone vs added chemotherapy for EBV-negative after treatment
This Phase 3 trial compares giving radiation alone versus giving radiation at the same time as chemotherapy for nasopharyngeal cancer. It focuses on people whose EBV test becomes undetectable after one cycle of chemotherapy, to see which approach works best and is safest.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05717790Recruiting
Nimotuzumab with chemo and radiation for advanced nose cancer
This trial tests whether adding nimotuzumab (an anti-EGFR antibody) to standard chemotherapy and radiation can improve outcomes for people with advanced nasopharyngeal carcinoma. It may help the cancer respond better and control it more effectively after treatment.
Baise City, GuangxiAges 18–70 - NCT05726370RecruitingPhase 2
Pembrolizumab plus chemo before surgery for recurrent head and neck cancer
This Phase 2 trial tests whether giving pembrolizumab (an immune therapy) plus chemotherapy before curative surgery can improve outcomes for people with resectable, recurrent head and neck squamous cell cancer. It also studies how these treatments affect the tumor and immune response using required tissue and blood samples.
Boston, MassachusettsAges 18 years+ - NCT05758389RecruitingPhase 2
Immunotherapy plus chemo for locally advanced head and neck cancer
This Phase 2 study tests whether tislelizumab (an immunotherapy) combined with chemotherapy works better for locally advanced head and neck squamous cell cancer. It aims to improve cancer control when the tumor is large and has not spread to distant organs.
Nanjing, JiangsuAges 18–75 - NCT05764044RecruitingPhase 3
Chemo after chemoradiation for HPV-positive cervical cancer
This Phase 3 study tests whether giving additional (adjuvant) chemotherapy after standard chemoradiation can help people whose blood test still shows cancer-related HPV DNA. It may help by lowering the risk of the cervical cancer coming back in people who have a positive blood biomarker after treatment.
Manaus, AmazonasAges 18–70 - NCT05789082RecruitingPhase 1/Phase 2
Divarasib for untreated lung cancer with KRAS G12C
This trial studies divarasib to see if it is safe and can shrink or control advanced lung cancer. Participants must have a KRAS G12C mutation and have not had prior treatment for their advanced disease.
Duarte, CaliforniaAges 18 years+ - NCT05800054Recruiting
Nutrition support program for people with esophageal cancer
This trial tests whether an “NST whole-course” nutrition management plan can improve nutrition status and reduce side effects during treatment for stage II–III esophageal cancer. It may help you stay stronger and tolerate cancer therapy better by carefully monitoring and adjusting nutrition.
Nanjing, JiangsuAges 18–75 - NCT05800574RecruitingPhase 2
Targeted neck radiation for p16-positive favorable throat cancer
This Phase 2 study tests whether a more precisely targeted radiation plan to the neck can work for people with p16-positive oropharynx cancer that is considered “favorable risk.” Doctors use special imaging to map where lymph nodes are likely involved, aiming to treat the right areas while avoiding unnecessary treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05819892RecruitingPhase 1
Dostarlimab with chemo and radiation for advanced womb cancer
This Phase 1 trial studies how safe and tolerable it is to add dostarlimab (an immunotherapy) to standard chemo and radiation, followed by more chemotherapy, for stage IIIC endometrial cancer that has spread to lymph nodes. It aims to see whether this combination can be given safely soon after surgery.
Houston, TexasAges 18 years+ - NCT05821556RecruitingPhase 2
New drug combo test for untreated metastatic pancreatic cancer
This Phase 2 study tests a combination of medicines (including valproic acid and a statin) along with standard chemotherapy for people with newly diagnosed metastatic pancreatic cancer. The goal is to improve cancer control before any prior pancreatic cancer treatments and to see how well the medicines work and are tolerated.
Naples, ItalyAges 18 years+ - NCT05827523RecruitingPhase 3
Surgery for ovarian cancer with or without heated chemotherapy
This trial studies whether adding a special heated chemotherapy treatment during surgery (called HIPEC) improves outcomes for some people with ovarian, fallopian tube, or primary peritoneal cancer. It compares surgery alone versus surgery plus HIPEC after you’ve had chemotherapy first.
Sejong, Chungcheongnam-doAges 18–80 - NCT05852717RecruitingPhase 2
Epcoritamab plus GDP chemotherapy for relapsed large B-cell lymphoma
This Phase 2 study tests epcoritamab combined with GDP chemotherapy to treat adults whose large B-cell lymphoma has come back or did not respond to prior treatment. It aims to improve how safely and effectively the disease can be controlled after standard chemotherapy.
Indianapolis, IndianaAges 18 years+ - NCT05857631Recruiting
After-surgery radiation schedule for cervical or uterine cancers
This trial studies a shorter, focused radiation schedule given after surgery for certain higher-risk cervical or endometrial (uterine) cancers. It may help reduce cancer recurrence while checking side effects in the bladder and bowel area.
Navi Mumbai, MaharahstraAges 18–80 - NCT05862168RecruitingPhase 2
Tislelizumab with chemotherapy before surgery for oral cancer
This trial studies giving tislelizumab (an immune treatment) plus chemotherapy before surgery to shrink and treat locally advanced oral squamous cell cancer. It aims to improve tumor response and outcomes, while checking safety.
HangzhouAges 18–75 - NCT05903092RecruitingPhase 2
Monalizumab plus durvalumab for small cell lung cancer
This Phase 2 trial tests whether adding monalizumab to durvalumab (two immune-targeting medicines) can improve outcomes in people with small cell lung cancer. You may be able to join if you have certain stage of small cell lung cancer and have not had the specific prior treatments the study allows.
Indianapolis, IndianaAges 18 years+
Hear when a new Cisplatin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cisplatin?
- Yes. Clin2 currently lists 486 recruiting cisplatin studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cisplatin trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cisplatin trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.